Pharmaceutical drugs: suspected anti-competitive agreements and conduct

The CMA is investigating alleged anti-competitive agreements and conduct in the pharmaceutical sector under Chapters I and II CA98 and Articles 101 and 102 TFEU.

Case timetable

Date Action
Q1 2019 (estimate) Decision on whether to issue a statement of objections.
May to Q1 2019 (estimate) Further investigation including further information gathering. CMA analysis and review of information gathered.
May 2018 Decision taken to proceed with investigation into certain conduct and parties.
October 2017 to May 2018 Initial investigation and information gathering. CMA analysis and review of information gathered.
October 2017 Investigation opened.

Change log

The following changes have been made to the case timetable since it was first published in October 2017:

Date of change Reason for change Change made to timetable
26 October 2018 Additional time needed to gather and analyse additional information Date for CMA decision on whether to issue a statement of objections changed from November 2018 to Q1 2019
19 April 2018 Additional time needed to gather and analyse additional information Date for completing initial investigation and information gathering changed from April 2018 to May 2018

Case information

On 10 October 2017, the Competition and Markets Authority (CMA) launched an investigation under Chapters I and II of the Competition Act 1998 (CA98) and Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU) into suspected breaches of competition law by various parties. The investigation relates to suspected anti-competitive agreements and/or concerted practices and suspected abuse of dominance in relation to the supply of certain generic pharmaceutical products.

The CMA has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation. Not all cases result in the CMA issuing a statement of objections.

Further detail of the CMA’s procedures in CA98 cases is available in our guidance.

Contacts

Assistant Project Directors

Sophie Mitchell (020 3738 6905, sophie.mitchell@cma.gov.uk)

Nathalie Lobel-Lastmann (020 3738 6789, nathalie.lobel-lastmann@cma.gov.uk)

Project Director

Fred Houwen (020 3738 6723, fred.houwen@cma.gov.uk)

Senior Responsible Officer

Ann Pope (020 3738 6786, ann.pope@cma.gov.uk)

Published 13 October 2017
Last updated 26 October 2018 + show all updates
  1. Updated case timetable published.
  2. Case timetable updated.
  3. Case timetable updated.
  4. First published.